

* Indicates a required field ☐ New start ☐ Reauthorization ☐ Restarting treatment ☐ Transitioning from: _____

SERVICES REQUESTED	Access Support Requested: ☐ Prior Authorization support request. If PA approved, provide PA approval number _____ with dates from: ____/____/____ to: ____/____/____. ☐ Appeals support request				
	Additional Services: ☐ JumpStart TM request ☐ Sogroya [®] Device Training: ☐ In-person ☐ Virtual ☐ Starter Kit ☐ NovoCare [®] Savings Offer (if eligible). For complete terms and conditions, visit SogroyaSavingsEligibility.com .				
	* Terms and conditions of JumpStartTM require active, timely prescriber support of Prior Authorization and/or Appeal documentation submission.				
	^b Patients who have been prescribed Sogroya[®] for an FDA-approved indication and who have commercial insurance may be eligible to receive a limited supply of free product from JumpStartTM. Patient is not eligible if he/she participates in or seeks reimbursement or submits a claim for reimbursement to any federal or state health care program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state health care program. JumpStartTM product is provided at no cost to the patient or the HCP, is not contingent on any product purchase, and the patient and HCP must not: (1) bill any third party for the free product, or (2) resell the free product. No purchase necessary.				
PATIENT/INSURANCE INFORMATION	Patient first name: *		Patient last name: *		DOB (MM/DD/YYYY): * / /
	Gender[†]: * ☐ Male ☐ Female		Preferred language: ☐ English ☐ Spanish ☐ Other:		
	Home address (No P.O. box):		City:	State:	Zip: *
	Shipping address (If different from Home Address):		City:	State:	Zip: *
	Primary guardian/caregiver: *		Relationship to patient:		
	Primary Email:		Primary phone:		
	Secondary guardian/caregiver:		Relationship to patient:		
	Secondary Email:		Secondary phone:		
	Primary medical insurance: (Please attach a copy of the insurance card if available)		Phone:		
	Subscriber name:		Subscriber ID:	Policy/group #:	
	Secondary medical insurance:		Phone:		
	DIAGNOSIS	What is the primary diagnosis for which you are prescribing Sogroya[®] (somapacitan-beco) injection? (required) *			
Growth Hormone Deficiency (GHD):		Idiopathic Short Stature (ISS):		Noonan Syndrome:	
☐ E23.0 - Hypopituitarism		☐ R62.52 - Short stature (child)		☐ Q87.1 - Congenital malformation syndromes predominantly associated with short stature	
☐ E23.1 - Drug-induced hypopituitarism		Small for Gestational Age (SGA):			
☐ E89.3 - Postprocedural hypopituitarism		☐ P05.10 - Newborn born small for gestational age			
Other diagnosis:					
ICD-10 code and description: _____					
If requesting JumpStartTM, please select both Prescription fields (required) * ☐ JumpStart TM Prescription ☐ Ongoing Prescription					
Sogroya [®] (somapacitan-beco) prefilled pen:		NovoFine [®] Needle:			
☐ 5mg ☐ 10mg ☐ 15mg		☐ 32G Tip (6mm) disposable needles			
Directions:		☐ PenMate [®] reusable cover for needles:			
Inject _____mg SC once weekly _____Days Supply _____Refills		☐ 1 ☐ 2			
PRESCRIPTION	Preferred pharmacy:		Pharmacy Phone:		Pharmacy Fax:
	Pharmacy address:		City:	State:	Zip:
	Height (cm): _____	Date: ____/____/____	GH stim test 1	GH stim test 2	IGF-1: _____
	Weight (kg): * _____	Date: ____/____/____	Date: ____/____/____	Date: ____/____/____	IGF BP-3: _____
	Growth velocity (cm/y): _____	Agent: _____	Agent: _____	Agent: _____	
	Bone age: _____	Date: ____/____/____	Results: _____	Results: _____	MRI has been completed: ☐ Yes ☐ No
	Prescriber name: *		License #: *		
	Practice name:		Office contact:		Preferred method of contact: ☐ Phone ☐ Fax ☐ Email
	DEA #:		Tax ID #:		NPI #: *
	Phone: *		Fax: *		Email: *
	Address: *		City: *		State: * Zip: *
	Prescriber release: * By signing below, I hereby certify that: (a) I am a licensed practitioner, in good standing under applicable state law; (b) the product being prescribed is to treat a diagnosis(es) consistent with indications and dosing described in the product's prescribing information; (c) the information I have provided on this enrollment form is, to the best of my knowledge, true, complete, and accurate in all respects; and (d) I have obtained the necessary authorization from the patient, or where appropriate the patient's parent, caregiver, and/or legal representative to use, disclose, share, and/or release the above-referenced information along with other protected health information (as defined in the Health Insurance Portability and Accountability Act of 1996 ("HIPAA")) for the sole purpose of providing patient assistance. Further, I appoint NovoCare [®] , on my behalf, to convey this prescription to the dispensing pharmacy. I will immediately notify Novo Nordisk Inc., its employees, or partners, including AssistRx, Inc. (collectively, "NovoCare [®] ") if the above-named patient, or where appropriate the patient's parent, caregiver, and/or legal representative, revokes their consent to share their PHI with NovoCare [®] . I give you permission to contact me, or the above named patient/Caregiver, with any questions related to NovoCare [®] .				
Prescriber signature (no signature stamps): *				Date: * / /	